🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Immunoglobulin A Nephropathy
Clinical trial register · United States · industry-sponsored

Immunoglobulin A Nephropathy Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 11 Florida 10 Alabama 8 Georgia 8 Colorado 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals5 Travere Therapeutics, Inc.2 Alexion Pharmaceuticals, Inc.2 Otsuka Pharmaceutical Development & Commercialization, Inc.2 Alpine Immune Sciences, Inc.1
State
California11 Florida10 Alabama8 Georgia8 Colorado7
All 26 states
Target enrolment
to
13 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
28
New Jersey, Ohio, Oklahoma, Tennessee
2026-08-26
Recruiting
Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT07024563IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis
Alexion Pharmaceuticals, Inc.
Phase 3
36
California, Colorado
2025-06-14
Recruiting
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
NCT06952426Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Observational
300
Massachusetts
2025-03-04
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho
2024-08-30
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
Alexion Pharmaceuticals, Inc.
Phase 3
579
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2024-03-29
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Alabama, California, Colorado, Florida, Illinois, Indiana, Iowa, Minnesota
2023-07-06
Active, closed
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alpine Immune Sciences, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Missouri
2023-03-15
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Alabama, California, Colorado, Florida, Georgia, Massachusetts, Michigan, New York
2022-04-05
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Iowa
2022-03-15
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
Travere Therapeutics, Inc.
Phase 2
67
California, Delaware, Florida, Iowa, Massachusetts, Michigan, Minnesota, Missouri
2021-08-12
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2020-12-11
Active, closed
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850Immunoglobulin A Nephropathy
Travere Therapeutics, Inc.
Phase 3
406
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2018-12-11
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/immunoglobulin-a-nephropathy

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.